Rafferty Asset Management
CPRX

Rafferty Asset Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Rafferty Asset Management’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.6M Sell
82,757
-37,975
-31% -$1.12M 0.01% 579
2026
Q1 		$2.99M Sell
120,732
-34,304
-22% -$817K 0.01% 516
2025
Q4 		$3.62M Sell
155,036
-2,008
-1% -$44.7K 0.01% 519
2025
Q3 		$3.09M Buy
157,044
+61,328
+64% +$1.26M 0.01% 543
2025
Q2 		$2.08M Sell
95,716
-8,983
-9% -$212K 0.01% 603
2025
Q1 		$2.54M Sell
104,699
-12,393
-11% -$279K 0.01% 514
2024
Q4 		$2.44M Sell
117,092
-5,398
-4% -$116K 0.01% 586
2024
Q3 		$2.44M Sell
122,490
-63,004
-34% -$1.17M 0.01% 581
2024
Q2 		$2.87M Sell
185,494
-301,280
-62% -$4.69M 0.01% 540
2024
Q1 		$7.76M Buy
486,774
+134,612
+38% +$2.03M 0.03% 357
2023
Q4 		$5.92M Sell
352,162
-158,273
-31% -$2.16M 0.03% 404
2023
Q3 		$5.97M Sell
510,435
-204,440
-29% -$2.73M 0.04% 353
2023
Q2 		$9.61M Buy
714,875
+250,208
+54% +$3.6M 0.05% 218
2023
Q1 		$7.7M Sell
464,667
-27,784
-6% -$458K 0.05% 254
2022
Q4 		$9.16M Buy
492,451
+87,742
+22% +$1.35M 0.08% 200
2022
Q3 		$5.19M Buy
404,709
+218,609
+117% +$2.59M 0.06% 330
2022
Q2 		$1.3M Sell
186,100
-45,408
-20% -$333K 0.01% 570
2022
Q1 		$1.92M Buy
231,508
+2,920
+1% +$20.6K 0.01% 614
2021
Q4 		$1.55M Buy
228,588
+35,802
+19% +$235K 0.01% 746
2021
Q3 		$1.02M Buy
192,786
+594
+0.3% +$3.25K 0.01% 808
2021
Q2 		$1.1M Sell
192,192
-243,632
-56% -$1.26M 0.01% 846
2021
Q1 		$2.01M Buy
435,824
+375,238
+619% +$1.49M 0.01% 627
2020
Q4 		$202K Sell
60,586
-172,744
-74% -$580K ﹤0.01% 990
2020
Q3 		$693K Buy
233,330
+148,429
+175% +$580K 0.01% 633
2020
Q2 		$392K Buy
84,901
+50,853
+149% +$228K 0.01% 767
2020
Q1 		$131K Sell
34,048
-328,248
-91% -$1.35M 0.01% 550
2019
Q4 		$1.36M Buy
362,296
+192,878
+114% +$902K 0.02% 476
2019
Q3 		$900K Buy
+169,418
New +$903K 0.01% 565

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Rafferty Asset Management's CPRX Position: Q2 2026 in Review

Rafferty Asset Management reduced its Catalyst Pharmaceutical (CPRX) stake by 31% in Q2 2026, selling an estimated $1.12M and leaving 82,757 shares worth $2.6M. The position accounts for 0.01% of the portfolio, ranked #579.

Rafferty Asset Management first reported a position in CPRX in Q3 2019 and has held it in 28 quarters since. The position peaked at $9.61M in Q2 2023. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • Rafferty Asset Management held 82,757 shares of Catalyst Pharmaceutical worth $2.6M as of Q2 2026.
  • Rafferty Asset Management sold 37,975 Catalyst Pharmaceutical shares in Q2 2026, an estimated $1.12M.
  • Catalyst Pharmaceutical made up 0.01% of Rafferty Asset Management's portfolio in Q2 2026, its #579 holding.
  • Rafferty Asset Management first reported a position in Catalyst Pharmaceutical in Q3 2019 and has held it in 28 quarters since.
  • Rafferty Asset Management's Catalyst Pharmaceutical position peaked at $9.61M in Q2 2023.
  • 396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Rafferty Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.